GILD Expands Trodelvy Approval
Gilead's Trodelvy receives FDA approval for unresectable locally advanced or metastatic triple-negative breast cancer
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
GILD Receives FDA Approval
Gilead Sciences receives FDA approval for Trodelvy to treat triple-negative breast cancer
GILD: FDA Approves Trodelvy
Gilead Sciences receives FDA approval for Trodelvy to treat adult patients with unresectable locally advanced or metastatic triple-negative breast cancer